Martino, M. et al. CART-cell therapy: recent advances and new evidence in multiple myeloma. Cancers 13, 2639 (2021).
Sivandzade, F. & Cucullo, L. Regenerative stem cell therapy for neurodegenerative diseases: an overview. Int. J. Mol. Sci. 22, 2153 (2021).
Kitada, T., DiAndreth, B., Teague, B. & Weiss, R. Programming gene and engineered-cell therapies with synthetic biology. Science 359, eaad1067 (2018).
Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46–62 (2020). This perspective provides an overview of current developments in immune cell therapies for cancer, infectious diseases and autoimmunity, and highlights cellular engineering advances addressing key challenges.
Fischbach, M. A., Bluestone, J. A. & Lim, W. A. Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med. 5, 179ps7 (2013).
Zhao, Z., Ukidve, A., Kim, J. & Mitragotri, S. Targeting strategies for tissue-specific drug delivery. Cell 181, 151–167 (2020).
Mount, N. M., Ward, S. J., Kefalas, P. & Hyllner, J. Cell-based therapy technology classifications and translational challenges. Philos. Trans. R. Soc. B: Biol. Sci. 370, 20150017 (2015).
Wang, L. L. W. et al. Cell therapies in the clinic. Bioeng. Transl. Med. 6, e10214 (2021). This review highlights the diversity and advantages of cell therapies, discusses 28 globally approved products and their clinical uses, analyses more than 1,700 active clinical trials and addresses the major biological, manufacturing and regulatory challenges in their clinical translation.
Vargason, A. M., Anselmo, A. C. & Mitragotri, S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 5, 951–967 (2021).
Wang, H. & Mooney, D. J. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat. Mater. 17, 761–772 (2018).
Li, Z. et al. Cell‐based delivery systems: emerging carriers for immunotherapy. Adv. Funct. Mater. 31, 2100088 (2021).
Yang, L., Yang, Y., Chen, Y., Xu, Y. & Peng, J. Cell-based drug delivery systems and their in vivo fate. Adv. Drug Deliv. Rev. 187, 114394 (2022).
Li, J. et al. Implantable and injectable biomaterial scaffolds for cancer immunotherapy. Front. Bioeng. Biotechnol. 8, 612950 (2020).
Adeyemi, S. A. & Choonara, Y. E. Current advances in cell therapeutics: a biomacromolecules application perspective. Expert. Opin. Drug. Deliv. 19, 521–538 (2022).
Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359–371 (2023).
Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood cancer J. 11, 69 (2021).
Arjomandnejad, M., Kopec, A. L. & Keeler, A. M. CAR-T regulatory (CAR-Treg) cells: engineering and applications. Biomedicines 10, 287 (2022).
Romano, M., Fanelli, G., Albany, C. J., Giganti, G. & Lombardi, G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front. Immunol. 10, 43 (2019).
Zhang, L., Meng, Y., Feng, X. & Han, Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomarker Res. 10, 1–19 (2022).
Bald, T., Krummel, M. F., Smyth, M. J. & Barry, K. C. The NK cell–cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat. Immunol. 21, 835–847 (2020).
Na, Y. R., Kim, S. W. & Seok, S. H. A new era of macrophage-based cell therapy. Exp. Mol. Med. 55, 1945–1954 (2023).
Lee, S., Kivimäe, S., Dolor, A. & Szoka, F. C. Macrophage-based cell therapies: the long and winding road. J. Control. Rel. 240, 527–540 (2016).
Hoang, D. M. et al. Stem cell-based therapy for human diseases. Signal. Transduct. Target. Ther. 7, 272 (2022).
Zakrzewski, W., Dobrzyński, M., Szymonowicz, M. & Rybak, Z. Stem cells: past, present, and future. Stem Cell Res. Ther. 10, 1–22 (2019).
Basile, G. et al. Emerging diabetes therapies: bringing back the β-cells. Mol. Metab. 60, 101477 (2022).
Yu, H., Yang, Z., Li, F., Xu, L. & Sun, Y. Cell-mediated targeting drugs delivery systems. Drug. Deliv. 27, 1425–1437 (2020).
Yousefpour, P., Ni, K. & Irvine, D. J. Targeted modulation of immune cells and tissues using engineered biomaterials. Nat. Rev. Bioeng. 1, 107–124 (2023).
Li, R., Chen, Z., Li, J., Dai, Z. & Yu, Y. Nano-drug delivery systems for T cell-based immunotherapy. Nano Today 46, 101621 (2022).
Ahn, Y. H. et al. A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy. Biomaterials 247, 119960 (2020).
Prakash, S. et al. Polymer micropatches as natural killer cell engagers for tumor therapy. ACS Nano 17, 15918–15930 (2023).
Sung, S., Steele, L. A., Risser, G. E. & Spiller, K. L. Biomaterial-assisted macrophage cell therapy for regenerative medicine. Adv. Drug Deliv. Rev. 199, 114979 (2023).
Liang, T. et al. Recent advances in macrophage-mediated drug delivery systems. Int. J. Nanomed. 16, 2703 (2021).
Li, Y. et al. Clinical progress and advanced research of red blood cells based drug delivery system. Biomaterials 279, 121202 (2021).
Kharbikar, B. N., Mohindra, P. & Desai, T. A. Biomaterials to enhance stem cell transplantation. Cell Stem Cell 29, 692–721 (2022).
Quizon, M. J. & García, A. J. Engineering β cell replacement therapies for type 1 diabetes: biomaterial advances and considerations for macroscale constructs. Annu. Rev. Pathol. Mech. Dis. 17, 485–513 (2022).
Adebowale, K. et al. Materials for cell surface engineering. Adv. Mater. https://doi.org/10.1002/adma.202210059 (2023). This review summarizes recent advances in decorating cell surfaces with nanoparticles, microparticles and polymeric coatings, focusing on enhancing carrier cells and their therapeutic effects.
Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A. & Irvine, D. J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035–1041 (2010).
Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707–716 (2018).
Scott, M. D., Murad, K. L., Koumpouras, F., Talbot, M. & Eaton, J. W. Chemical camouflage of antigenic determinants: stealth erythrocytes. Proc. Natl Acad. Sci. USA 94, 7566–7571 (1997).
Pan, C. et al. Polymerization‐mediated multifunctionalization of living cells for enhanced cell‐based therapy. Adv. Mater. 33, 2007379 (2021).
Shields, C. W. et al. Cellular backpacks for macrophage immunotherapy. Sci. Adv. 6, eaaz6579 (2020).
Kapate, N. et al. Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury. PNAS Nexus 3, pgad434 (2024).
Kapate, N. et al. Polymer backpack‐loaded tissue infiltrating monocytes for treating cancer. Adv. Healthc. Mater. 2304144 https://doi.org/10.1002/adhm.202304144 (2024).
Farina, M., Alexander, J. F., Thekkedath, U., Ferrari, M. & Grattoni, A. Cell encapsulation: overcoming barriers in cell transplantation in diabetes and beyond. Adv. Drug Deliv. Rev. 139, 92–115 (2019). This review summarizes encapsulation strategies from academic and industrial research, including technologies in advanced preclinical and clinical phases, and highlights stimulus-responsive systems for improved therapeutic delivery in cell transplantation.
Sun, L. et al. Induced cardiomyocytes-integrated conductive microneedle patch for treating myocardial infarction. Chem. Eng. J. 414, 128723 (2021).
Lathuiliere, A. et al. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies. Brain 139, 1587–1604 (2016).
Yang, L. et al. A biodegradable hybrid inorganic nanoscaffold for advanced stem cell therapy. Nat. Commun. 9, 3147 (2018).
Ye, Y. et al. Microneedles integrated with pancreatic cells and synthetic glucose‐signal amplifiers for smart insulin delivery. Adv. Mater. 28, 3115–3121 (2016).
Xue, D., Hsu, E., Fu, Y.-X. & Peng, H. Next-generation cytokines for cancer immunotherapy. Antib. Ther. 4, 123–133 (2021).
Jones, R. B. et al. Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials 117, 44–53 (2017).
Xie, Y.-Q. et al. Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells. Biomater. Sci. 7, 1345–1357 (2019).
Eskandari, S. K. et al. Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter. Sci. Transl. Med. 12, eaaw4744 (2020).
Liu, Y. et al. Cytokine conjugation to enhance T cell therapy. Proc. Natl Acad. Sci. USA 120, e2213222120 (2023).
Hou, X. et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 15, 41–46 (2020).
Stephan, M. T., Stephan, S. B., Bak, P., Chen, J. & Irvine, D. J. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 33, 5776–5787 (2012).
Hao, M. et al. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci. Transl. Med. 12, eaaz6667 (2020).
Trowbridge, J. J., Xenocostas, A., Moon, R. T. & Bhatia, M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat. Med. 12, 89–98 (2006).
Loukogeorgakis, S. P. et al. Donor cell engineering with GSK3 inhibitor-loaded nanoparticles enhances engraftment after in utero transplantation. Blood 134, 1983–1995 (2019).
Yu, D. et al. Hydrogen‐bonded organic framework (HOF)‐based single‐neural stem cell encapsulation and transplantation to remodel impaired neural networks. Angew. Chem. 134, e202201485 (2022).
Kapate, N. et al. A backpack-based myeloid cell therapy for multiple sclerosis. Proc. Natl Acad. Sci. USA 120, e2221535120 (2023).
Liu, S. et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J. Hematol. Oncol. 14, 1–17 (2021).
Kumbhojkar, N. et al. Neutrophils bearing adhesive polymer micropatches as a drug-free cancer immunotherapy. Nat. Biomed. Eng. 8, 579–592 (2024).
Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847–856 (2018).
Chen, X. et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy. Mol. Ther. Oncol. 21, 144–157 (2021).
Ghasemi, A. et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat. Cancer 5, 240–261 (2023).
Agarwalla, P. et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat. Biotechnol. 40, 1250–1258 (2022).
Anselmo, A. C. et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 7, 11129–11137 (2013).
Anselmo, A. C. et al. Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: synergy between physical, chemical and biological approaches. Biomaterials 68, 1–8 (2015).
Brenner, J. S. et al. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nat. Commun. 9, 2684 (2018).
Ukidve, A. et al. Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function. Proc. Natl Acad. Sci. USA 117, 17727–17736 (2020).
Zhao, Z., Ukidve, A., Gao, Y., Kim, J. & Mitragotri, S. Erythrocyte leveraged chemotherapy (ELeCt): nanoparticle assembly on erythrocyte surface to combat lung metastasis. Sci. Adv. 5, eaax9250 (2019).
Zhao, Z. et al. Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. Nat. Biomed. Eng. 5, 441–454 (2021).
Ding, Y. et al. RBC-hitchhiking chitosan nanoparticles loading methylprednisolone for lung-targeting delivery. J. Control, Rel. 341, 702–715 (2022).
Wang, C. et al. Multifunctional theranostic red blood cells for magnetic‐field‐enhanced in vivo combination therapy of cancer. Adv. Mater. 26, 4794–4802 (2014).
Ferguson, L. T. et al. Dual affinity to RBCs and target cells (DART) enhances both organ-and cell type-targeting of intravascular nanocarriers. ACS Nano 16, 4666–4683 (2022).
Zhao, Z. et al. Engineering of living cells with polyphenol‐functionalized biologically active nanocomplexes. Adv. Mater. 32, 2003492 (2020).
Zhao, Z. et al. Red blood cell anchoring enables targeted transduction and re‐administration of AAV‐mediated gene therapy. Adv. Sci. 9, 2201293 (2022).
Zelepukin, I. et al. Nanoparticle-based drug delivery via RBC-hitchhiking for the inhibition of lung metastases growth. Nanoscale 11, 1636–1646 (2019).
Schmid, D. et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat. Commun. 8, 1–12 (2017).
Huang, B. et al. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci. Transl. Med. 7, 291ra94 (2015).
Shi, C. et al. Trojan horse nanocapsule enabled in situ modulation of the phenotypic conversion of TH17 cells to Treg cells for the treatment of multiple sclerosis in mice. Adv. Mater. 35, 2210262 (2023).
Gao, C. et al. Supramolecular macrophage–liposome marriage for cell‐hitchhiking delivery and immunotherapy of acute pneumonia and melanoma. Adv. Funct. Mater. 31, 2102440 (2021).
Yang, L. et al. Live macrophage-delivered doxorubicin-loaded liposomes effectively treat triple-negative breast cancer. ACS Nano 16, 9799–9809 (2022).
Im, S. et al. Harnessing the formation of natural killer–tumor cell immunological synapses for enhanced therapeutic effect in solid tumors. Adv. Mater. 32, 2000020 (2020).
Mosquera, J., García, I. & Liz-Marzán, L. M. Cellular uptake of nanoparticles versus small molecules: a matter of size. Acc. Chem. Res. 51, 2305–2313 (2018).
Rennick, J. J., Johnston, A. P. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266–276 (2021).
Dou, H. et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108, 2827–2835 (2006).
Choi, M.-R. et al. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7, 3759–3765 (2007).
Evans, M. A. et al. Macrophage‐mediated delivery of hypoxia‐activated prodrug nanoparticles. Adv. Ther. 3, 1900162 (2020).
Qi, Y., Yan, X., Xia, T. & Liu, S. Use of macrophage as a Trojan horse for cancer nanotheranostics. Mater. Des. 198, 109388 (2021).
Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug. Discov. 21, 799–820 (2022).
Choi, J. et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 33, 4195–4203 (2012).
De Oliveira, S., Rosowski, E. E. & Huttenlocher, A. Neutrophil migration in infection and wound repair: going forward in reverse. Nat. Rev. Immunol. 16, 378–391 (2016).
Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159–175 (2013).
Xue, J. et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 12, 692 (2017).
Luo, Z. et al. Neutrophil hitchhiking for drug delivery to the bone marrow. Nat. Nanotechnol. 18, 647–656 (2023).
Shi, M. et al. Dual functional monocytes modulate bactericidal and anti‐inflammation process for severe osteomyelitis treatment. Small 16, 1905185 (2020).
Kim, H. et al. Gold nanoparticle‐carrying T cells for the combined immuno‐photothermal therapy. Small 19, 2301377 (2023).
Wu, M. et al. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma. Nat. Commun. 9, 4777 (2018).
Sun, P. et al. A smart nanoparticle-laden and remote-controlled self-destructive macrophage for enhanced chemo/chemodynamic synergistic therapy. ACS Nano 14, 13894–13904 (2020).
Ye, B. et al. Neutrophils mediated multistage nanoparticle delivery for prompting tumor photothermal therapy. J. Nanobiotechnol. 18, 1–14 (2020).
Li, Z. et al. Small gold nanorods laden macrophages for enhanced tumor coverage in photothermal therapy. Biomaterials 74, 144–154 (2016).
Li, Z. et al. Cell-borne 2D nanomaterials for efficient cancer targeting and photothermal therapy. Biomaterials 133, 37–48 (2017).
Pinho, S., Macedo, M. H., Rebelo, C., Sarmento, B. & Ferreira, L. Stem cells as vehicles and targets of nanoparticles. Drug. Discov. Today 23, 1071–1078 (2018).
Cao, B., Yang, M., Zhu, Y., Qu, X. & Mao, C. Stem cells loaded with nanoparticles as a drug carrier for in vivo breast cancer therapy. Adv. Mater. 26, 4627–4631 (2014).
Lai, Y.-H. et al. Stem cell–nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy. Nat. Commun. 14, 285 (2023).
Anselmo, A. C. et al. Monocyte-mediated delivery of polymeric backpacks to inflamed tissues: a generalized strategy to deliver drugs to treat inflammation. J. Control. Rel. 199, 29–36 (2015).
Gilbert, J. B., O’Brien, J. S., Suresh, H. S., Cohen, R. E. & Rubner, M. F. Orientation‐specific attachment of polymeric microtubes on cell surfaces. Adv. Mater. 25, 5948–5952 (2013).
Polak, R. et al. Liposome‐loaded cell backpacks. Adv. Healthc. Mater. 4, 2832–2841 (2015).
Wang, L. L.-W. et al. Preclinical characterization of macrophage-adhering gadolinium micropatches for MRI contrast after traumatic brain injury in pigs. Sci. Transl. Med. 16, eadk5413 (2024).
Alapan, Y. et al. Soft erythrocyte-based bacterial microswimmers for cargo delivery. Sci. Robot. 3, eaar4423 (2018).
Tang, J. et al. Cardiac cell–integrated microneedle patch for treating myocardial infarction. Sci. Adv. 4, eaat9365 (2018).
Bagó, J. R. et al. Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma. Biomaterials 90, 116–125 (2016).
Xue, Y. et al. LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing. Nat. Commun. 15, 739 (2024).
Webber, M. J., Khan, O. F., Sydlik, S. A., Tang, B. C. & Langer, R. A perspective on the clinical translation of scaffolds for tissue engineering. Ann. Biomed. Eng. 43, 641–656 (2015).
Drury, J. L. & Mooney, D. J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 24, 4337–4351 (2003).
Lee, H. et al. A decade of advances in single‐cell nanocoating for mammalian cells. Adv. Healthc. Mater. 10, 2100347 (2021).
Singh, A. et al. Enhanced lubrication on tissue and biomaterial surfaces through peptide-mediated binding of hyaluronic acid. Nat. Mater. 13, 988–995 (2014).
Rossi, N. A., Constantinescu, I., Brooks, D. E., Scott, M. D. & Kizhakkedathu, J. N. Enhanced cell surface polymer grafting in concentrated and nonreactive aqueous polymer solutions. J. Am. Chem. Soc. 132, 3423–3430 (2010).
Kim, H. et al. General and facile coating of single cells via mild reduction. J. Am. Chem. Soc. 140, 1199–1202 (2018).
Mahal, L. K., Yarema, K. J. & Bertozzi, C. R. Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis. Science 276, 1125–1128 (1997).
Wilson, J. T., Krishnamurthy, V. R., Cui, W., Qu, Z. & Chaikof, E. L. Noncovalent cell surface engineering with cationic graft copolymers. J. Am. Chem. Soc. 131, 18228–18229 (2009).
Teramura, Y., Kaneda, Y., Totani, T. & Iwata, H. Behavior of synthetic polymers immobilized on a cell membrane. Biomaterials 29, 1345–1355 (2008).
Park, J. et al. Engineering the surface of therapeutic “living” cells. Chem. Rev. 118, 1664–1690 (2018).
Le, Y. & Scott, M. D. Immunocamouflage: the biophysical basis of immunoprotection by grafted methoxypoly(ethylene glycol) (mPEG). Acta Biomater. 6, 2631–2641 (2010).
Yang, S. H. et al. Mussel-inspired encapsulation and functionalization of individual yeast cells. J. Am. Chem. Soc. 133, 2795–2797 (2011).
Wang, D., Toyofuku, W. M. & Scott, M. D. The potential utility of methoxypoly (ethylene glycol)-mediated prevention of rhesus blood group antigen RhD recognition in transfusion medicine. Biomaterials 33, 3002–3012 (2012).
Bochenek, M. A. et al. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat. Biomed. Eng. 2, 810–821 (2018).
Veiseh, O. et al. Size-and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat. Mater. 14, 643–651 (2015).
Dhawan, A. et al. Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children. J. Hepatol. 72, 877–884 (2020).
Snow, B. et al. A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease. Parkinsonism Relat. Disord. 61, 88–93 (2019).
de Vos, P., Lazarjani, H. A., Poncelet, D. & Faas, M. M. Polymers in cell encapsulation from an enveloped cell perspective. Adv. Drug Deliv. Rev. 67, 15–34 (2014).
Chaimov, D. et al. Innovative encapsulation platform based on pancreatic extracellular matrix achieve substantial insulin delivery. J. Control. Rel. 257, 91–101 (2017).
Calafiore, R. et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 29, 137–138 (2006).
Basta, G. et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care 34, 2406–2409 (2011).
Tuch, B. E. et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care 32, 1887–1889 (2009).
Vegas, A. J. et al. Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. Nat. Biotechnol. 34, 345–352 (2016).
Matlaga, B. F., Yasenchak, L. P. & Salthouse, T. N. Tissue response to implanted polymers: the significance of sample shape. J. Biomed. Mater. Res. 10, 391–397 (1976).
Shapiro, A. J. et al. Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Rep. Med. 2, 100466 (2021).
Chang, R. et al. Nanoporous immunoprotective device for stem-cell-derived β-cell replacement therapy. ACS Nano 11, 7747–7757 (2017).
Sivaraj, D. et al. Hydrogel scaffolds to deliver cell therapies for wound healing. Front. Bioeng. Biotechnol. 9, 660145 (2021).
Garg, R. K. et al. Capillary force seeding of hydrogels for adipose-derived stem cell delivery in wounds. Stem Cell Transl. Med. 3, 1079–1089 (2014).
Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 1, 10–29 (2016).
Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med. 4, e10143 (2019).
Mandal, A., Clegg, J. R., Anselmo, A. C. & Mitragotri, S. Hydrogels in the clinic. Bioeng. Transl. Med. 5, e10158 (2020).
Bailey, S. R. & Maus, M. V. Gene editing for immune cell therapies. Nat. Biotechnol. 37, 1425–1434 (2019).
Ellis, G. I., Sheppard, N. C. & Riley, J. L. Genetic engineering of T cells for immunotherapy. Nat. Rev. Genet. 22, 427–447 (2021).
Hamilton, E. et al. PRIME™ IL-15 (RPTR-147): preliminary clinical results and biomarker analysis from a first-in-human phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients. J. Immunother. Cancer 8, A479–A480 (2020).
Falcetti, C. & Offner, O. Torben Straight Nissen joins Repertoire® Immune Medicines as Chief Executive Officer. Company refocusing on the potential of its DECODE™ platform to develop transformative immune medicines. businesswire https://go.nature.com/4cYiABC (2022).
Aijaz, A. et al. Biomanufacturing for clinically advanced cell therapies. Nat. Biomed. Eng. 2, 362–376 (2018).
Batty, C. J., Bachelder, E. M. & Ainslie, K. M. Historical perspective of clinical nano and microparticle formulations for delivery of therapeutics. Trends Mol. Med. 27, 516–519 (2021).
Stewart, S. A., Domínguez-Robles, J., Donnelly, R. F. & Larrañeta, E. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Polymers 10, 1379 (2018).
Li, J., Wu, C., Chu, P. K. & Gelinsky, M. 3D printing of hydrogels: rational design strategies and emerging biomedical applications. Mater. Sci. Eng. R: Rep. 140, 100543 (2020).
Zhang, H. et al. Microfluidics for nano-drug delivery systems: from fundamentals to industrialization. Acta Pharm. Sin. B 13, 3277–3299 (2023).
Kim, H. U., Roh, Y. H., Mun, S. J. & Bong, K. W. Discontinuous dewetting in a degassed mold for fabrication of homogeneous polymeric microparticles. ACS Appl. Mater. Interfaces 12, 53318–53327 (2020).
Wang, J.-Y. & Wang, Y. Particle replication in non-wetting templates: a platform for engineering shape-and size-specific janus particles. Angew. Chem. Int. Ed. Engl. 52, 6580–6589 (2012).
Li, J. & Mooney, D. J. Designing hydrogels for controlled drug delivery. Nat. Rev. Mater. 1, 16071 (2016).
Kakkar, A., Traverso, G., Farokhzad, O. C., Weissleder, R. & Langer, R. Evolution of macromolecular complexity in drug delivery systems. Nat. Rev. Chem. 1, 63 (2017).
Zhang, Y., Chan, H. F. & Leong, K. W. Advanced materials and processing for drug delivery: the past and the future. Adv. Drug Deliv. Rev. 65, 104–120 (2013).
Chen, R. et al. Biomaterial-assisted scalable cell production for cell therapy. Biomaterials 230, 119627 (2020). This review discusses how biomaterials enhance cell production by creating biomimetic environments that support cell adhesion and proliferation, maintain cell characteristics, and improve production efficiency and quality control through automated, Good Manufacturing Practice-compliant methods.
Roh, K.-H., Nerem, R. M. & Roy, K. Biomanufacturing of therapeutic cells: state of the art, current challenges, and future perspectives. Annu. Rev. Chem. Biomol. Eng. 7, 455–478 (2016).
Chen, A. K.-L., Chen, X., Choo, A. B. H., Reuveny, S. & Oh, S. K. W. Critical microcarrier properties affecting the expansion of undifferentiated human embryonic stem cells. Stem Cell Res. 7, 97–111 (2011).
Carletti, E., Motta, A. & Migliaresi, C. Scaffolds for tissue engineering and 3D cell culture. Methods Mol. Biol. 695, 17–39 (2011).
Cheung, A. S., Zhang, D. K., Koshy, S. T. & Mooney, D. J. Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat. Biotechnol. 36, 160–169 (2018).
Ashley, E. A. Towards precision medicine. Nat. Rev. Genet. 17, 507–522 (2016).
Manzari, M. T. et al. Targeted drug delivery strategies for precision medicines. Nat. Rev. Mater. 6, 351–370 (2021).
Facklam, A. L., Volpatti, L. R. & Anderson, D. G. Biomaterials for personalized cell therapy. Adv. Mater. 32, 1902005 (2020). This review underscores the importance of biomaterials in tissue regeneration, therapeutic protein delivery and cancer immunotherapy, focusing on advancements in engineering material properties and functionalities tailored for personalized cell therapies.
Keymeulen, B. et al. Encapsulated stem cell-derived β cells exert glucose control in patients with type 1 diabetes. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-02055-5 (2023).
Philippidis, A. First patient dosed with VCTX210, a cell therapy for type 1 diabetes: ViaCyte and CRISPR Therapeutics are evaluating an immune-evasive cell replacement therapy that they developed to help patients produce their own insulin. Genet. Eng. Biotechnol. News 42, 10–11 (2022).
Fernandez, E. et al. MVX-ONCO-1 in advanced refractory cancers: Safety, feasibility, and preliminary efficacy results from all HNSCC patients treated in two ongoing clinical trials. J. Clin. Oncol. 39, e18005 (2021).
Mach, N. et al. LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy. Ann. Oncol. 34, S1286 (2023).
Kauper, K. et al. Continuous intraocular drug delivery lasting over a decade: ciliary neurotrophic factor (CNTF) secreted from Neurotech’s NT-501 implanted in subjects with retinal degenerative disorders. Investig. Ophthalmol. Vis. Sci. 64, 3680–3680 (2023).
Birch, D. G. et al. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am. J. Ophthalmol. 156, 283–292.e1 (2013).
Chew, E. Y. et al. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. Ophthalmology 126, 540–549 (2019).
Brizuela, C. et al. Cell-based regenerative endodontics for treatment of periapical lesions: a randomized, controlled phase I/II clinical trial. J. Dental Res. 99, 523–529 (2020).
Evans, M. A. et al. Macrophage-mediated delivery of light activated nitric oxide prodrugs with spatial, temporal and concentration control. Chem. Sci. 9, 3729–3741 (2018).
Tomás, R. M., Martyn, B., Bailey, T. L. & Gibson, M. I. Engineering cell surfaces by covalent grafting of synthetic polymers to metabolically-labeled glycans. Acs Macro Lett. 7, 1289–1294 (2018).
Zhao, Y. et al. Surface-anchored framework for generating RhD-epitope stealth red blood cells. Sci. Adv. 6, eaaw9679 (2020).
Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91–96 (2022).
Barberio, A. E. et al. Cancer cell coating nanoparticles for optimal tumor-specific cytokine delivery. ACS Nano 14, 11238–11253 (2020).
Wayteck, L. et al. Hitchhiking nanoparticles: reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes. Biomaterials 77, 243–254 (2016).
Merivaara, A. et al. Preservation of biomaterials and cells by freeze-drying: change of paradigm. J. Control. Rel. 336, 480–498 (2021).
Wikström, J. et al. Viability of freeze dried microencapsulated human retinal pigment epithelial cells. Eur. J. Pharm. Sci. 47, 520–526 (2012).
Auvinen, V.-V. et al. Effects of nanofibrillated cellulose hydrogels on adipose tissue extract and hepatocellular carcinoma cell spheroids in freeze-drying. Cryobiology 91, 137–145 (2019).
Hamilton, J. R. et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-02085-z (2024).
Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813–820 (2017).
Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436–443 (2023).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s44222-024-00214-0